Volume of white matter hyperintensities in healthy adults: Contribution of age, vascular risk factors, and inflammation-related genetic variants

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 3, 2012, Pages 361-369

  Raz, Naftali ^a   Yang, Yiqin ^a   Dahle, Cheryl L ^a   Land, Susan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE; Aging; ApoE; Brain; CRP; Frontal lobe; Homocysteine; Interleukin; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; IMAGE ENHANCEMENT; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; WHITE MATTER; WHITE MATTER HYPERINTENSITY;

ADULT; AGE FACTORS; AGED; ALLELES; APOLIPOPROTEIN E2; BIOLOGICAL MARKERS; BRAIN; C-REACTIVE PROTEIN; FEMALE; GENETIC VARIATION; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPROTEINS, LDL; MAGNETIC RESONANCE IMAGING; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NERVE FIBERS, MYELINATED; ORGAN SIZE; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; RISK FACTORS;

EID: 84856070362     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.08.007     Document Type: Article

References (104)

1. Raz N., Kennedy K.M. A systems approach to age-related change: neuroanatomic changes, their modifiers, and cognitive correlates. Imaging the Aging Brain 2009, 43-70. Oxford University Press, New York, NY. W. Jagust, M. D'Esposito (Eds.).
2. Kemper T.L. Neuroanatomical and neuropathological changes during aging and in dementia. Clinical Neurology of Aging 1994, 3-67. Oxford University Press, New York. M.L. Albert, E.J.E. Knoepfel (Eds.).
3. Hedden T., Gabrieli J.D.E. Insights into the ageing mind: a view from cognitive neuroscience. Nat. Rev. Neurosci. 2004, 5:87-96.
4. Gunning-Dixon F.M., Brickman A.M., Cheng J.C., Alexopoulos G.S. Aging of cerebral white matter: a review of MRI findings. Int. J. Geriatr. Psychiatry 2009, 24:109-117.
5. Peters A. The effects of normal aging on myelin and nerve fibers: a review. J. Neurocytol. 2002, 31:581-593.
6. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., Pratt E., Sherin J.E., Altshuler L.L., Mintz J., Gitlin M.J., Subotnik K.L., Nuechterlein K.H. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 2009, 113:322-331.
7. Sullivan E.V., Adalsteinsson E., Pfefferbaum A. Selective age-related degradation of anterior callosal fiber bundles quantified in vivo with fiber tracking. Cereb. Cortex 2006, 16:1030-1039.
8. Madden D.J., Bennett I.J., Song A.W. Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol. Rev. 2009, 19:415-435.
9. Hackinski V.C., Potter P., Merskey H. Leuko-araiosis. Arch. Neurol. 1987, 44:21-23.
10. Pantoni L., Garcia J.H. Cognitive impairment and cellular/vascular changes in the cerebral white matter. Ann. N.Y. Acad. Sci. 1997, 826:92-102.
11. De Leeuw F.E., De Groot J.C., Achten E., Oudkerk M., Ramos L.M.P., Heijboer R., Hofman A., Jolles J., Van Gijn J., Breteler M.M.B. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J. Neurol. Neurosurg. Psychiatry 2001, 70:9-14.
12. Young V.G., Halliday G.M., Krill J.J. Neuropathologic correlates of white matter. Neurology 2008, 71:804-811.
13. Kertesz A., Black S.E., Tokar G., Benke T., Carr T., Nicholson L. Periventricular and subcortical hyperintensities on magnetic resonance imaging. 'Rims, caps, and unidentified bright objects'. Arch. Neurol. 1988, 45:404-408.
14. Fazekas F., Niederkorn K., Schmidt R., Offenbacher H., Horner S., Bertha G., Lechner H. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988, 19:1285-1288.
15. Inzitari D., Diaz F., Fox A., Hachinski V.C., Steingart A., Lau C., Donald A., Wade J., Mulic H., Merskey H. Vascular risk factors and leuko-araiosis. Arch. Neurol. 1987, 44:42-47.
16. DeCarli C., Murphy, Tranh M., Grady C.L., Haxby J.V., Gillette J.A., Salerno J.A., Gonzales-Aviles A., Horwitz B., Rapoport S.I., Schapiro M.B. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995, 45:2077-2084.
17. Raz N., Rodrigue K.M., Acker J.D. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 2003, 117:1169-1180.
18. Atwood L.D., Wolf P.A., Heard-Costa N.L., Massaro J.M., Beiser A., D'Agostino R.B., DeCarli C. Genetic variation in white matter hyperintensity volume in the Framingham study. Stroke 2004, 35:1609-1613.
19. Kochunov P. Whole brain and regional hyperintense white matter volume and blood pressure overlap of genetic loci produced by bivariate, whole-genome linkage analyses. Stroke 2010, 41:2137-2142.
20. Carmelli D., DeCarli C., Swan G.E., Jack L.M., Reed T., Wolf P.A., M.B.L. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998, 29:1177-1181.
21. Ikram M.A., Seshadri S., Bis J.C., Fornage M., DeStefano A.L., Aulchenko Y.S., Debette S., Lumley T., Folsom A.R., van den Herik E.G., Bos M.J., Beiser A., Cushman M., Launer L.J., Shahar E., Struchalin M., Du Y., Glazer N.L., Rosamond W.D., Rivadeneira F., Kelly-Hayes M., Lopez O.L., Coresh J., Hofman A., DeCarli C., Heckbert S.R., Koudstaal P.J., Yang Q., Smith N.L., Kase C.S., Rice K., Haritunians T., Roks G., de Kort P.L., Taylor K.D., de Lau L.M., Oostra B.A., Uitterlinden A.G., Rotter J.I., Boerwinkle E., Psaty B.M., Mosley T.H., van Duijn C.M., Breteler M.M., Longstreth W.T., Wolf P.A. Genomewide association studies of stroke. N. Engl. J. Med. 2009, 360:1718-1728.
22. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21.
23. Roses A.D. Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Ann. N.Y. Acad. Sci. 1996, 802:50-57.
24. Cherbuin N., Leach L.S., Christensen H., Anstey K.J. Neuroimaging and APOE genotype: a systematic qualitative review. Dement. Geriatr. Cogn. Disord. 2007, 24:348-362.
25. Bigler E.D., Lowry C.M., Kerr B., Tate D.F., Hessel C.D., Earl H.D., Miller M.J., Rice S.A., Smith K.H., Tschanz J.T., Welsh-Bohmer K., Plassman B., Victoroff J. Role of white matter lesions, cerebral atrophy, and APOE on cognition in older persons with and without dementia: the Cache County, Utah, study of memory and aging. Neuropsychology 2003, 17:339-352.
26. He J., Iosif A.M., Lee D.Y., Martinez O., Chu S., Carmichael O., Mortimer J.A., Zhao Q., Ding D., Guo Q., Galasko D., Salmon D.P., Dai Q., Wu Y., Petersen R.C., Hong Z., Borenstein A.R., DeCarli C. Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase. Arch. Neurol. 2010, 67:1231-1237.
27. Paternoster L., Chen W., Sudlow C.L.M. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19000 subjects. Stroke 2009, 40:2020-2026.
28. Lemmens R. Association of apolipoprotein E ε2 with white matter disease but not with microbleeds. Stroke 2007, 38:1185-1188.
29. Schmidt R., Schmidt H., Fazekas F., Schumacher M., Niederkorn K., Kapeller P., Weinrauch V., Kostner G.M. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997, 28:951-956.
30. Hall J.E. The renin-angiotensin system: renal actions and blood pressure regulation. Compr. Ther. 1991, 17:8-17.
31. Cambien F. The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction. Clin. Genet. 1994, 46(1 Spec No):94-101.
32. Amar K., MacGowan S., Wilcock G., Lewis T., Scott M. Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int. J. Geriatr. Psychiatry 1998, 13:585-590.
33. Sierra C., Coca A., Gómez-Angelats E., Poch E., Sobrino J., de la Sierra A. Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension 2002, 39:343-347.
34. Purandare N., Oude Voshaar R.C., Davidson Y., Gibbons L., Hardicre J., Byrne J., McCollum C., Jackson A., Burns A., Mann D.M. Deletion/insertion polymorphism of the angiotensin-converting enzyme gene and white matter hyperintensities in dementia: a pilot study. J. Am. Geriatr. Soc. 2006, 54:1395-1400.
35. Hou Z., Yuan Y., Zhang Z., Hou G., You J., Bai F. The D-allele of ACE insertion/deletion polymorphism is associated with regional white matter volume changes and cognitive impairment in remitted geriatric depression. Neurosci. Lett. 2010, 479:262-266.
36. Markus H.S. Genes, endothelial function and cerebral small vessel disease in man. Exp. Physiol. 2008, 93:121-127.
37. Brattström L., Israelsson B., Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 1989, 19(Suppl 1):35-44.
38. Rodrigo R., Passalacqua W., Araya J., Orellana M., Rivera G. Homocysteine and essential hypertension. J. Clin. Pharmacol. 2003, 43:1299-1306.
39. Casas J.P., Hingorani A.D., Bautista L.E., Pankaj Sharma P. Meta-analysis of genetic studies in ischemic stroke. Thirty-two genes involving approximately 18000 cases and 58000 controls. Arch. Neurol. 2004, 61:1652-1662.
40. de Lau L.M.L., van Meurs J.B.J., Uitterlinden A.G., Smith A.D., Refsum H., Johnston C., Breteler M.M.B. Genetic variation in homocysteine metabolism, cognition, and white matter lesions. Neurobiol. Aging 2010, 31:2020-2022.
41. Watfa G., Marteau J.B., Rossignol P., Kearney-Schwartz A., Fay R., Bracard S., Felblinger J., Boivin J.M., Lacolley P., Visvikis-Siest S., Benetos A., Zannad F. Association study of gene polymorphisms involved in vascular alterations in elderly hypertensives with subjective memory complaints. Dement. Geriatr. Cogn. Disord. 2010, 30:440-448.
42. Stankovic S., Majkic-Singh N. Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors. Crit. Rev. Clin. Lab. Sci. 2010, 47:72-123.
43. Lazzerini P., Capecchi P., Selvi E., Lorenzini S., Bisogno S., Galeazzi M., Laghi Pasini F. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun. Rev. 2007, 6:503-509.
44. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 2002, 50:2041-2056.
45. Finch C.E. Evolution in health and medicine Sackler colloquium: evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition. PNAS 2010, 107:1718-1724.
46. Brod S.A. Unregulated inflammation shortens human functional longevity. Inflamm. Res. 2000, 49:561-570.
47. Schmitz T., Chew L.-J. Cytokines and myelination in the central nervous system. Thescientificworldjo 2008, 8:1119-1147.
48. Rothwell N.J. Cytokines - killers in the brain?. J. Physiol. 1999, (Pt 1):3-17.
49. Yamasaki Y., Matsuura N., Shozuhara H., Onodera H., Itoyama Y., Kogue K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26.
50. Hayes A., Green E.K., Pritchard A., Harris J.M., Zhang Y., Lambert J.C., Chartier-Harlin M.C., Pickering-Brown S.M., Lendon C.L., Mann D.M. A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:1475-1477.
51. Allan S.M. Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat. Proc. Natl Acad. Sci. 2000, 97.
52. Didier N., Romero I.A., Créminon C., Wijkhuisen A., Grassi J., Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J. Neurochem. 2003, 96:246-254.
53. Baune B.T., Ponath G., Rothermundt M., Roesler A., Berger K. Association between cytokines and cerebral MRI changes in the aging brain. J. Geriatr. Psychiatry Neurol. 2009, 22:23-24. March.
54. Stroemer R.P., Rothwell N.J. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 1997, 17:597-604.
55. Hurme M., Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur. J. Immunol. 1998, 28:2598-2602.
56. Dziedzic T., Slowik A., Pera J., Szczudlik A. Interleukin 1 beta polymorphism (-511) and risk of stroke due to small vessel disease. Cerebrovasc. Dis. 2005, 20:299-303.
57. Kauffman M.A., Moron D.G., Consalvo D., Bello R., Kochen S. Association study between interleukin 1 beta gene and epileptic disorders: a HuGe review and meta-analysis. Genet. Med. 2008, 10:83-88.
58. Di Bona D., Plaia A., Vasto S., Cavallone L., Lescai F., Franceschi C., Licastro F., Colonna-Romano G., Lio D., Candore G., Caruso C. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res. Rev. 2008, 59:155-163.
59. Papiol S., Molina V., Desco M., Rosa A., Reig S., Gispert J.D., Sanz J., Palomo T., Fañanás L. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. NeuroImage 2005, 27:1002-1006.
60. Papiol S., Molina V., Desco M., Rosa A., Reig S., Sanz J., Palomo T., Fañanás L. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008, 7:796-801.
61. Fornage M., Chiang Y.A., O'Meara E.S., Psaty B.M., Reiner A.P., Siscovick D.S., Tracy R.P., Longstreth W.T.J. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008, 39:1952-1959.
62. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon I.R.O., Criqui M. Markers of inflammation and cardiovascular disease: application to clinical and public health practice, a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
63. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
64. Van Dijk E.J., Prins N.D., Vermeer S.E., Vrooman H.A., Hofman A., Koudstaal P.J., Breteler M.M.B. C-reactive protein and cerebral small-vessel disease: the Rotterdam scan study. Circulation 2005, 112:900-905.
65. Wright C.B., Moon Y., Paik M.C., Brown T.R., Rabbani L., Yoshita M., DeCarli C., Sacco R., Elkind M.S. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009, 40:3466-3471. Epub 2009 Aug 20.
66. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J. Med. 2005, 35:1685-1695.
67. Haan M.N., Aiello A.E., West N.A., Jagust W.J. C-reactive protein and rate of dementia in carriers and non carriers of Apolipoprotein APOE4 genotype. Neurobiol. Aging 2008, 29:1774-1782.
68. Reitz C., Berger K., De Maat M.P.M., Stoll M., Friedrichs F., Kardys I., Witteman J.C.M., Breteler M.M.B. CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO Study. Stroke 2007, 38:2356-2359.
69. Shen J., Arnett D.K., Parnell L.D., Peacock J.M., Lai C.Q., Hixson J.E., Tsai M.Y., Province M.A., Straka R.J., Ordovas J.M. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diab. Care 2008, 31:910-915. Epub 2008 Feb 19.
70. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1:385-401.
71. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
72. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
73. Gunning-Dixon F.M., Raz N. Neuroanatomical correlates of selected executive functions in middle-aged and older adults: a prospective MRI study. Neuropsychologia 2003, 41:1929-1941.
74. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-428.
75. Steiger J.H. Tests for comparing elements of a correlation matrix. Psychol. Bull. 1980, 87:245-251.
76. Sachdev P.S., Parslow R., Wen W., Anstey K.J., Easteal S. Sex differences in the causes and consequences of white matter hyperintensities. Neurobiol. Aging 2009, 30:946-956.
77. Raz N., Gunning F.M., Head D., Dupuis J.H., McQuain J., Briggs S.D., Loken W.J., Thornton A.E., Acker J.D. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb. Cortex 1997, 7:268-282.
78. Apter N.S., Halstead W.C., Heimburger R.F. Impaired cerebral functions in essential hypertension. Am. J. Psychiatry 1951, 107:808-813.
79. Raz N., Yang Y.Q., Rodrigue K.M., Kennedy K.M., Lindenberger U., Ghisletta P. White matter deterioration in 15months: latent growth curve models in healthy adults. Neurobiol. Aging 2010, Dec 29. [Epub ahead of print].
80. Kuller L.H., Margolis K.L., Gaussoin S.A., Bryan N.R., Kerwin D., Limacher M., Wassertheil-Smoller S., Williamson J., Robinson J.G. Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial. J. Clin. Hypertens (Greenwich) 2010, 12:203-212. W.s.H.I.M.S.R. Group.
81. Raz N., Lindenberger U., Rodrigue K.M., Kennedy K.M., Head D., Williamson A., Dahle C., Gerstorf D., Acker J.D. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb. Cortex 2005, 15:1676-1689.
82. Yoshita M., Fletcher E., Harvey D., Ortega M., Martinez O., Mungas D.M., Reed B.R., DeCarli C.S. Extent and distribution of white matter hyperintensities in normal aging. MCI, and AD, Neurology 2006, 67:2192-2198.
83. Gouw A.A., van der Flier W.M., Fazekas F., van Straaten E.C., Pantoni L., Poggesi A., Inzitari D., Erkinjuntti T., Wahlund L.O., Waldemar G., Schmidt R., Scheltens P., Barkhof F., Group L.S. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008, 39:1414-1420.
84. Polvikoski T.M., van Straaten E.C., Barkhof F., Sulkava R., Aronen H.J., Niinistö L., Oinas M., Scheltens P., Erkinjuntti T., Kalaria R.N. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010, 75:2071-2078.
85. Payabvash S., Souza L.C., Wang Y., Schaefer P.W., Furie K.L., Halpern E.F., Gonzalez R.G., Lev M.H. Regional ischemic vulnerability of the brain to hypoperfusion: the need for location specific computed tomography perfusion thresholds in acute stroke patients. Stroke 2011, 42:1255-1260.
86. Brown W.R., Thore C.R. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol. Appl. Neurobiol. 2011, 37:56-74.
87. Levy B.I., Schiffrin E.L., Mourad J.-J., Agostini D., Vicaut E., Safar M.E., Struijker-Boudier H.A.J. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008, 118:968-976.
88. Hummler E., Rossier B.C. Physiological and pathophysiological role of the epithelial sodium channel in the control of blood pressure. Kidney Blood Press. Res. 1996, 19:160-165.
89. Nobili F., Rodriguez G., Marenco S., De Carli F., Gambaro M., Castello C., Pontremoli R., Rosadini G. Regional cerebral blood flow in chronic hypertension. A correlative study. Stroke 1993, 24:1148-1153.
90. Hajjar I., Zhao P., Alsop D., Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010, 56:859-864.
91. Enzinger C., Smith S., Fazekas F., Drevin G., Ropele S., Nichols T., Behrens T., Schmidt R., Matthews P.M. Lesion probability maps of white matter hyperintensities in elderly individuals: results of the Austrian stroke prevention study. J. Neurol. 2006, 253:1064-1070.
92. Marstrand J.R., Garde E., Rostrup E., Ring P., Rosenbaum S., Mortensen E.L., Larsson H.B. Cerebral perfusion and cerebrovascular reactivity are reduced in white matter hyperintensities. Stroke 2002, 33:972-976.
93. Brickman A.M., Zahra A., Muraskin J., Steffener J., Holland C.M., Habeck C., Borogovac A., Ramos M.A., Brown T.R., Asllani I., Stern Y. Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res. 2009, 172:117-120.
94. Kraut M.A., Beason-Held L.L., Elkins W.D., Resnick S.M. The impact of magnetic resonance imaging-detected white matter hyperintensities on longitudinal changes in regional cerebral blood flow. J. Cereb. Blood Flow Metab. 2008, 28:190-197.
95. Raz N., Rodrigue K.M., Kennedy K.M., Acker J.D. Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology 2007, 21:149-157.
96. Artero S., Tiemeier H., Prins N.D., Sabatier R., Breteler M.M., Ritchie K. Neuroanatomical localisation and clinical correlates of white matter lesions in the elderly. J. Neurol. Neurosurg. Psychiatry 2004, 75:1304-1308.
97. Katrinchak C., Fritz K. Clinical implications of C-reactive protein as a predictor of vascular risk. J. Am. Acad. Nurse Pract. 2007, 19:335-340.
98. Black S., Kushner I., Samols D. C-reactive protein. J. Biol. Chem. 2004, 279:48487-48490.
99. Szolnoki Z., Somogyvári F., Kondacs A., Szabó M., Fodor L., Bene J., Melegh B. Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis. Acta Neurol. Scand. 2004, 109:222-227.
100. Brady C.B., Gaziano J.M., Cxypoliski R.A., Guarino P.D., Kaufman J.S., Warren S.R., Hartigan P., Goldfarb D.S., Jamison R.L. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. Am. J. Kidney Dis. 2009, 54:440-449. Epub 2009 Jul 23.
101. Goto M. Inflammaging (inflammation+aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory?. Biosci. Trends 2008, 2:218-230.
102. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N.Y. Acad. Sci. 2000, 908:244-254.
103. Strandgaard S., Paulson O.B. Cerebral blood flow in untreated and treated hypertension. Neth. J. Med. 1995, 47:180-184.
104. Jennings J.R., Mendelson D.N., Muldoon M., Ryan, Ryan C.M., Gianaros P.J., Raz N., Aizenstein H. Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure. J. Hum. Hypertens. 2011, the Alzheimer's Disease Neuroimaging Initiative.